EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. - Wikidata - awgldk - TriplyDB

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.

http://www.wikidata.org/entity/Q35067875

about

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients Understanding the interplay between host immunity and Epstein-Barr virus in NPC patients PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model Trial Watch-Immunostimulation with cytokines in cancer therapy The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer.Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis.Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives Epstein-Barr virus (EBV)-associated epithelial and non-epithelial lesions of the oral cavity.Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro Gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p inhibit growth of EBV-positive nasopharyngeal carcinoma.Purification and identification of a polysaccharide from medicinal mushroom Amauroderma rude with immunomodulatory activity and inhibitory effect on tumor growth EBV-encoded RNA via TLR3 induces inflammation in nasopharyngeal carcinoma.Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival EBV-miR-BART10-3p facilitates epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma by targeting BTRC The copy number of Epstein-Barr virus latent genome correlates with the oncogenicity by the activation level of LMP1 and NF-κB.IL-27 induces the expression of IDO and PD-L1 in human cancer cells.Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures.PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma.Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.Varicella-Zoster Virus Downregulates Programmed Death Ligand 1 and Major Histocompatibility Complex Class I in Human Brain Vascular Adventitial Fibroblasts, Perineurial Cells, and Lung Fibroblasts Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature Millepachine, a potential topoisomerase II inhibitor induces apoptosis via activation of NF-κB pathway in ovarian cancer.SWATH-based proteomics identified carbonic anhydrase 2 as a potential diagnosis biomarker for nasopharyngeal carcinoma.Programmed death-ligand 1 is upregulated in intrahepatic lymphoepithelioma-like cholangiocarcinoma SNHG8 is identified as a key regulator of epstein-barr virus(EBV)-associated gastric cancer by an integrative analysis of lncRNA and mRNA expression Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response.PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.Novel roles and therapeutic targets of Epstein-Barr virus-encoded latent membrane protein 1-induced oncogenesis in nasopharyngeal carcinoma.Investigational drugs for nasopharyngeal carcinoma.Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options.Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.Are virus-induced cancers more sensitive to checkpoint inhibitors?PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load.NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.

P2860

Q26797478-2CF917EC-C244-4AA0-A1D7-B3C67CE68B05 Q26823898-5236B652-DE3F-4D72-B60C-93B4FB80E0B0 Q27313748-B5710EFE-7109-45C2-B430-077C0229C2C1 Q28078725-903E0362-4264-45E2-B6B4-72DF61CE972E Q30278553-3CC978AB-B0DE-48E3-A3D4-DEB80B27AC29 Q33648621-B71B1C11-8B82-410B-B6F4-CFB181D0B0C3 Q33788235-A9895B92-F9ED-4C80-8A28-B439100422C0 Q33884361-63D9864B-9894-4E52-BEA1-AA7D7BAAB249 Q33884691-C311283C-5B25-41B6-A9F9-DCB6617EF9AC Q33889053-350B9A44-A60C-4F7D-BC29-ABA7A7379041 Q35770856-2353F423-955D-463D-AE8D-5C20ECE7C06D Q35781438-2E63F28D-2D64-4303-A6C4-78624893C811 Q36232168-6912B023-BDB0-4BC4-B9D4-59A52135F868 Q36414449-0CEC6B74-AAF9-494A-BE35-12003113CE58 Q36544290-D6C2153F-B534-4F11-9620-97AA36836E23 Q36545054-EE22B51F-AEFA-4D6F-99E4-9CD7D3D7C75F Q36561585-97DCB691-5115-4B39-9E57-DC14FE2EB5ED Q36562258-98AF5DFC-DE09-4ED6-A186-F35A3EB50E3D Q36685395-6B5B2E1F-D1E7-4DE1-AC88-C93413F566C1 Q36821248-9283BB15-6ACD-4693-A311-D046092A9E7E Q37046786-5A51F28F-4CDD-4EBD-87D1-03464641954A Q37085912-3DE9C507-3893-40BA-A4E2-F612ED77D3DB Q37086039-142CF116-6D1E-44FF-8EDA-07CDBE459C51 Q37340738-3B2624AB-317A-44B2-862B-4438BD80901F Q37415466-949A6875-3455-401E-8EB3-E9B116726EF1 Q37584406-BA94A8D3-7F43-48B0-9DB4-A1C4F11FBB1E Q37588443-48281102-BBDA-4829-833F-D92F1D0916CA Q37602007-7D99C43F-3323-42A0-A411-BDB1A7981FDC Q37688436-36C93D8C-6A96-4561-87C7-77EFD5D80968 Q37697107-D823602F-74CB-4B53-9DA3-F555A39E4D72 Q37705026-246EACAC-5705-4317-9F98-506D16BCC2F0 Q38271540-A164AB71-79F7-4349-9197-70B6EBD7774D Q38568602-06E4423A-77AA-4E02-A685-3C3C27ABDEEB Q38690528-68711698-CCE5-4886-A732-B45D525F67BF Q38700735-20982725-4BC5-4A84-93E9-638A3669240F Q38720593-829A0E29-3B73-444C-825E-519CFB4F42F1 Q38789263-B43167F9-C96B-4EBE-A0B9-FCB5CB72A59E Q38832379-8527A638-A2D9-4C95-9FA1-791FC82D1D72 Q38931346-896D3F59-C01D-421A-B396-489F489AF233 Q38988815-CACB7EC9-4B3B-47E0-9045-4157C71C1848

P2860

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.

http://www.wikidata.org/entity/Q35067875

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

EBV-driven LMP1 and IFN-γ up-r ...... ions for oncotargeted therapy.

@ast

EBV-driven LMP1 and IFN-γ up-r ...... ions for oncotargeted therapy.

@en

type

label

EBV-driven LMP1 and IFN-γ up-r ...... ions for oncotargeted therapy.

@ast

EBV-driven LMP1 and IFN-γ up-r ...... ions for oncotargeted therapy.

@en

prefLabel

EBV-driven LMP1 and IFN-γ up-r ...... ions for oncotargeted therapy.

@ast

EBV-driven LMP1 and IFN-γ up-r ...... ions for oncotargeted therapy.

@en

P1433

Q35067875-444BC41C-9F3F-476A-917F-5A82F33CA3E4

P1476

Q35067875-D11A680C-3C40-41F4-BD33-F4D750B48BAC

P2093

Q35067875-01CEEB12-6554-4B6C-9FA5-FB25C83DCE38

Q35067875-14865B9B-BE6F-4DC8-AB3D-95CD6753D6B7

Q35067875-210E58F3-2124-46D0-8050-10C1EDC6BDDB

Q35067875-25526EF9-91D9-4F9F-8877-7506BAF25B44

Q35067875-2C6D9660-C387-4D63-8B4F-A4D3CF2CDA86

Q35067875-48B24764-3392-4C0D-8E28-6F7EAFDDEE45

Q35067875-507DBD54-0677-4910-A98A-F0419E7DE812

Q35067875-54ADEA3F-99AC-456B-BB05-CDF947E6F721

Q35067875-63513D5B-28CE-4886-8F8E-9F241D37D8DC

Q35067875-723A4D52-4971-4E18-A334-E0E3A4F0D817

P2860

Q35067875-040A93DF-42D2-4A61-9B1C-2A37BBCC652B

Q35067875-04DA5B54-817A-474D-AB14-8225D37D30C2

Q35067875-06C2FD00-D429-4CB7-BE0F-C81D4E13D9E3

Q35067875-0BCB88BE-B78B-45DC-B073-C9E82E100CDD

Q35067875-0DE6F4DC-62E2-4BD4-B5EB-02B8562BCBF1

Q35067875-0E2D0EBB-6002-4EB9-8485-2E9295ACC202

Q35067875-13F31B93-7426-4F38-9CA5-597579AD9F63

Q35067875-1CC0DC8A-631E-4CB8-B0D0-EC14F709E2E1

Q35067875-23C53244-E84D-435B-A1B6-909AD666F99E

Q35067875-2A70B3DD-3FC7-4A8C-8E76-EC4A14DD70D3

P304

Q35067875-CF5E09DF-17EF-4264-889A-68A3D326D229

P31

Q35067875-0F201ADF-D88A-459E-BA62-638C9F333FFD

P356

Q35067875-448BC7B7-4089-47A1-A3CD-848BD3FEEFC8

P407

Q35067875-BBCDF934-BE54-4C1D-9469-CD1CE71D330C

P433

Q35067875-A7FD1EA5-4740-45EC-B788-1AE13131B39C

P478

Q35067875-3DDA6CC8-259F-45C4-9B94-0E54DB6E7F7E

P577

Q35067875-AAF61576-1A94-49A2-A3F9-3C9884FE9BF0

P5875

Q35067875-9CBA0845-CDC6-4738-B425-EADC1E7C20E5

P698

Q35067875-772F73F2-FF03-457C-8499-035EA6B17B76

P932

Q35067875-A0765D0D-B00A-4EED-AFEE-D50BF036E37E

P356

ONCOTARGET.2608

P1433

P1476

EBV-driven LMP1 and IFN-γ up-r ...... ions for oncotargeted therapy.

@en

P2093

Cong Xue

http://www.w3.org/2001/XMLSchema#string

Hongyun Zhao

http://www.w3.org/2001/XMLSchema#string

Jianhua Zhan

http://www.w3.org/2001/XMLSchema#string

Jianwei Zhang

http://www.w3.org/2001/XMLSchema#string

Li Zhang

http://www.w3.org/2001/XMLSchema#string

Nan Chen

http://www.w3.org/2001/XMLSchema#string

Peiyu Huang

http://www.w3.org/2001/XMLSchema#string

Shaodong Hong

http://www.w3.org/2001/XMLSchema#string

Shiyang Kang

http://www.w3.org/2001/XMLSchema#string

Tao Qin

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Emerging treatment options for nasopharyngeal carcinoma

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Tumor metastasis: molecular insights and evolving paradigms

P304

12189-12202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.2608

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267738143

http://www.w3.org/2001/XMLSchema#string

P698

25361008

http://www.w3.org/2001/XMLSchema#string

P932

4322961

http://www.w3.org/2001/XMLSchema#string